aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
06 Junio 2023 - 7:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics
company engaged in the discovery and development of first-in-class
medicines from its proprietary tRNA synthetase platform, today
announced multiple presentations at the International Union of
Biochemistry and Molecular Biology’s 13th International Symposium
of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to
take place June 4 – 9 in Ontario, Canada.
“As a leader in the field of tRNA biology, we
look forward to highlighting some of the recent findings from our
platform at AARS 2023,” said Leslie A. Nangle, Ph.D., Vice
President, Research at aTyr. “In these presentations we describe
the process from concept to clinical proof-of-concept for
efzofitimod, our lead tRNA synthetase-derived candidate in
development for interstitial lung disease, and how we have applied
that same process to identify extracellular targets for two
additional tRNA synthetase candidates from our platform.
Furthermore, we present exciting findings that solidify a
connection between patients with certain genetic conditions and
lower circulating levels of the tRNA synthetase HARS, which forms
the active portion of efzofitimod. As these patients exhibit
dysregulated respiratory immune responses, this data provides
rationale for a link between human extracellular HARS deficiency
and diseases with respiratory symptoms.”
Extracellular tRNA synthetases represent a class
of proteins that may play important roles in regulating cellular
responses to certain disease states, in particular, cellular stress
and imbalances in tissue homeostasis. aTyr is focused on
elucidating novel pathways mediated through extracellular tRNA
synthetases and creating new biologics to modulate these pathways
by developing protein therapies based on extracellular tRNA
synthetase fragments.
Details of the presentations appear below. The
posters will be available on the aTyr website once presented.
Title: Clinical Proof-of-Concept for a
Novel Therapeutic Based on Histidyl-tRNA Synthetase for Treatment
of Interstitial Lung DiseasesFormat:
PresentationPresenter: Leslie A. Nangle,
Ph.D.Date and Time: Tuesday, June 6, 2023, at 3:30
p.m.
Title: Identification of Key Fibrotic
Extracellular Targets for Alanyl- and Aspartyl-tRNA Synthetases
Format: Poster PresentationDate and
Time: Tuesday, June 6, 2023, at 8:10 p.m.
Title: Circulating
His-tRNA Synthetase is Reduced in Patients Harboring the Usher
Syndrome Type 3B-Linked Mutation Y454SFormat:
Poster PresentationDate and Time: Tuesday, June 6,
2023, at 8:10 p.m.
Title: tRNA Biology Industry Panel
Format: PanelPanelist: Leslie A.
Nangle, Ph.D.Date and Time: Wednesday, June 7,
2023, at 11:40 a.m.
About
Efzofitimod
aTyr is developing efzofitimod as a potential
therapeutic for patients with fibrotic lung disease. Efzofitimod, a
fusion protein comprised of the immunomodulatory domain of
histidyl-tRNA synthetase fused to the FC region of a human
antibody, is a selective modulator of neuropilin-2 that
downregulates innate and adaptive immune response in inflammatory
disease states. aTyr’s lead indication for efzofitimod is pulmonary
sarcoidosis, a major form of interstitial lung disease. Clinical
proof-of-concept for efzofitimod was recently established in a
Phase 1b/2a multiple-ascending dose, placebo-controlled study of
efzofitimod in patients with pulmonary sarcoidosis, which
demonstrated safety and a consistent dose response and trends of
benefit of efzofitimod compared to placebo on key efficacy
endpoints, including steroid reduction, lung function, clinical
symptoms and inflammatory biomarkers. aTyr is currently conducting
EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in
pulmonary sarcoidosis.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of first-in-class medicines from its
proprietary tRNA synthetase platform. aTyr’s research and
development efforts are concentrated on a newly discovered area of
biology, the extracellular functionality and signaling pathways of
tRNA synthetases. aTyr has built a global intellectual property
estate directed to a potential pipeline of protein compositions
derived from 20 tRNA synthetase genes and their extracellular
targets. aTyr’s primary focus is efzofitimod, a clinical-stage
product candidate which binds to the neuropilin-2 receptor and is
designed to downregulate immune engagement in fibrotic lung
disease. For more information, please visit
http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “believes,” “expects,”
“intends,” “may,” “plans,” “forward,” “potential,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements include, among others,
statements regarding potential therapeutic benefits and
applications of efzofitimod and research and development activities
related to future tRNA synthetase candidates. These forward-looking
statements also reflect our current views about our plans,
intentions, expectations, strategies and prospects, which are based
on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions,
expectations, strategies and prospects, as reflected in or
suggested by these forward-looking statements, are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. All forward-looking
statements are based on estimates and assumptions by our management
that, although we believe to be reasonable, are inherently
uncertain. Furthermore, actual results may differ materially from
those described in these forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, uncertainty regarding
geopolitical and macroeconomic events, risks associated with the
discovery, development and regulation of our product candidates,
the risk that we or our partners may cease or delay preclinical or
clinical development activities for any of our existing or future
product candidates for a variety of reasons (including difficulties
or delays in patient enrollment in planned clinical trials), the
possibility that existing collaborations could be terminated early,
and the risk that we may not be able to raise the additional
funding required for our business and product development plans, as
well as those risks set forth in our most recent Annual Report on
Form 10-K, Quarterly Report on Form 10-Q and in our subsequent SEC
filings. Except as required by law, we assume no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:Ashlee DunstonDirector,
Investor Relations and Corporate
Communicationsadunston@atyrpharma.com
aTyr Pharma (NASDAQ:LIFE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
aTyr Pharma (NASDAQ:LIFE)
Gráfica de Acción Histórica
De May 2023 a May 2024